Premium
Retinal Vein Occlusion : Treatment by series of 3 Ranibizumab IVT
Author(s) -
GONZALEZ C
Publication year - 2011
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2011.339.x
Subject(s) - medicine , ranibizumab , branch retinal vein occlusion , visual acuity , macular edema , ophthalmology , fluorescein angiography , occlusion , retinal , edema , surgery , bevacizumab , chemotherapy
Purpose To evaluate the functional, anatomical, vascular flow, anti‐ exudative effects of intravitreal injections(IVT) for Retinal Vein Occlusion ,by a protocol with 3 Ranibizumab IVT series, and the recurrences frequency at 3 years evolution. Methods 17 eyes of 17 patients with Retinal Vein Occlusion received intravitreous Ranibizumab, 3 times, every 4 weeks in an inductive treatment. The next injections depended on the follow‐up results and were done by series of 3. First and 2 months’ interval follow‐up exams included ETDRS visual acuity (VA), complete ophthalmic examination, optical coherence tomography (OCT), and fluorescein angiography (FA).VA and OCT were done before each IVT. We want to evaluate the incidence of this protocol on the exudation and frequency of recurrence and so on the number of IVT needed. Results VA improved in 16 eyes, stabilized in 1. Diffuse edema was 53% normalised ,total thickness was 60% less in the average follow‐up, cysts 100% disappeared in 75% cases, in 60% were diminished in size , volume and number, by OCT. At Angiography, no leakage in 65% cases, cystoids macular edema disappeared, vascular abnormalities diminished. Most of patients had good functional, anatomical results, with few IVT needed, no scars in the retina. Inductive treatment was sufficient in 5 cases, needed 2 IVT Series in 27% cases, failed in no cases. This protocol was compared ,discussed . Conclusion The results with improved visual acuity, reduction of exudation at OCT, vessel’s leakage and structure normalized at FA, suggest this protocol, with series of 3 Ranibizumab IVT, seems effective, more retinal protective. This protocol seems attractive, specific indication criteria and its indication must be optimized.